UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
DEFENDANT SOLSTICE BIOMEDICAL, INC.'S OPENING CLAIM CONSTRUCTION BRIEF
Marcus Delgado (Del. Bar No. 5178) Christy Bauer (Del. Bar No. 6492) Peter Vassiliev (Del. Bar No. 6830) CALDERWOOD & HARKNESS LLP 1201 Market Street, Suite 2500 Wilmington, DE 19801 Telephone: (302) 658-7400 Facsimile: (302) 658-7401 mdelgado@calderwoodharkness.com cbauer@calderwoodharkness.com pvassiliev@calderwoodharkness.com
Attorneys for Defendant Solstice Biomedical, Inc.
Filed: October 28, 2024
TABLE OF CONTENTS
TABLE OF AUTHORITIES
Cases
Statutes
Other Authorities
I. INTRODUCTION
Plaintiff Apex Surgical Innovations, Inc. ("Apex") filed this patent infringement action on May 9, 2024, alleging that Defendant Solstice Biomedical, Inc.'s ("Solstice") PrecisionEdge™ line of laparoscopic trocar assemblies — specifically, the PE-5000, PE-12000, and PE-15000 Series — infringes three Apex utility patents directed to components and subsystems of minimally invasive surgical access devices. The patents at issue are:
1. U.S. Patent No. 9,814,237 ("the '237 Patent"), entitled "Locking Seal Assembly for Minimally Invasive Surgical Access Device," which issued on November 14, 2017, and is set to expire on June 22, 2035. Apex asserts Claims 1, 3, 7, and 12 of the '237 Patent.
2. U.S. Patent No. 10,271,884 ("the '884 Patent"), entitled "Retractable Blade Deployment Mechanism for Trocar Systems," which issued on April 30, 2019, and is set to expire on September 15, 2036. Apex asserts Claims 1, 2, 5, 9, and 14 of the '884 Patent.
3. U.S. Patent No. 10,932,105 ("the '105 Patent"), entitled "Integrated Insufflation Valve and Seal for Laparoscopic Trocar," which issued on March 2, 2021, and is set to expire on January 10, 2038. Apex asserts Claims 1, 4, and 8 of the '105 Patent.
The named inventor on all three asserted patents is Dr. Raymond Szabo, who serves as Vice President of Engineering at Apex Surgical Innovations, Inc. All three patents are assigned to Apex.
Pursuant to the Court's Scheduling Order (D.I. 42), the parties have identified a total of nine disputed claim terms for construction at the Markman hearing currently scheduled for November 18, 2024. On October 22, 2024, the parties exchanged their respective Proposed Claim Constructions and Identification of Extrinsic Evidence in accordance with Local Patent Rule 4.2. As set forth in the parties' Joint Claim Construction Chart filed on October 25, 2024 (D.I. 78), the parties were unable to reach agreement on any of the nine disputed terms.
As demonstrated throughout this brief, Solstice's proposed constructions for each of the nine disputed claim terms are firmly grounded in the intrinsic record — that is, the claim language itself, the patent specifications, and the prosecution histories of the three asserted patents. Solstice's proposed constructions accurately reflect how a person of ordinary skill in the art at the time of the inventions would have understood each term when read in the context of the claims, the specification, and the relevant prior art.
By contrast, Apex's proposed constructions systematically seek to broaden the claims far beyond what the specifications disclose and, critically, beyond the scope that the applicant argued to the United States Patent and Trademark Office ("USPTO") during prosecution of the patents. In multiple instances, Apex's proffered constructions attempt to recapture claim scope that was explicitly surrendered during prosecution to overcome prior art rejections. Apex cannot be permitted to tell the USPTO one thing to obtain its patents and then tell this Court something different to expand their reach. The prosecution history estoppel doctrine exists precisely to prevent this kind of claim-scope manipulation.
The proper construction of these nine terms is central to the resolution of the infringement and invalidity issues in this case. For the reasons set forth in detail below, Solstice respectfully requests that the Court adopt Solstice's proposed constructions for each of the disputed terms.
II. LEGAL STANDARD
A. Claim Construction Principles
Claim construction is a matter of law for the Court. Markman v. Westview Instruments, Inc., 52 F.3d 967, 979 (Fed. Cir. 1995) (en banc), aff'd, 517 U.S. 370 (1996). The purpose of claim construction is to determine the meaning and scope of the patent claims, which define the boundaries of the patentee's right to exclude. Id. at 976.
The Federal Circuit's en banc decision in Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005), sets forth the governing framework for claim construction. Under Phillips, the words of a claim "are generally given their ordinary and customary meaning," which is "the meaning that the term would have to a person of ordinary skill in the art in question at the time of the invention, i.e., as of the effective filing date of the patent application." Id. at 1312–13. This inquiry is objective: the question is not what any particular individual subjectively understood the term to mean, but rather what a hypothetical person of ordinary skill in the art, familiar with the relevant technology and the patent literature, would have understood the claim language to mean when read in the context of the entire patent. Id. at 1313.
In Teva Pharmaceutical USA, Inc. v. Sandoz, Inc., 574 U.S. 318 (2015), the Supreme Court clarified the standard of review applicable to claim construction, holding that while the ultimate construction of a claim term is a question of law reviewed de novo, any subsidiary findings of fact — such as findings regarding the knowledge of a person of ordinary skill in the art or the meaning of technical terms — are subject to a clearly erroneous standard of review on appeal. Id. at 325–27. This deference framework underscores the importance of the district court's careful consideration of the factual underpinnings of claim construction, including the intrinsic and extrinsic evidence.
B. Role of Intrinsic Evidence
The Federal Circuit has consistently held that the intrinsic evidence — consisting of the claims, the specification, and the prosecution history — is the most significant source of the legally operative meaning of disputed claim terms. Phillips, 415 F.3d at 1314; Ridgeway & Co. v. Conceptronic, Inc., 90 F.3d 1576, 1582 (Fed. Cir. 1996). The analysis begins, and in many cases ends, with the intrinsic record.
Claim Language. The claim language itself is the primary source of claim meaning. Innova/Pure Water, Inc. v. Safari Water Filtration Sys., Inc., 381 F.3d 1111, 1116 (Fed. Cir. 2004). The context in which a disputed term is used within the claim, as well as the other claims of the patent, can be "highly instructive" in resolving disputes over claim meaning. Phillips, 415 F.3d at 1314. When a claim term has a plain and ordinary meaning that is clear and unambiguous, the Court need not resort to extrinsic evidence unless the intrinsic record compels a different construction. O2 Micro Int'l Ltd. v. Beyond Innovation Tech. Co., 521 F.3d 1351, 1361 (Fed. Cir. 2008).
Specification. The specification is the "single best guide to the meaning of a disputed term." Phillips, 415 F.3d at 1315 (quoting Vitronics, 90 F.3d at 1582). The specification "may reveal a special definition given to a claim term by the patentee that differs from the meaning it would otherwise possess. In such cases, the inventor's lexicography governs." Id. at 1316. Additionally, the specification may "reveal an intentional disclaimer, or disavowal, of claim scope by the inventor." Id. Where the specification consistently describes a term in a particular way throughout all disclosed embodiments, the claims should generally be construed consistently with that description. See Bell Atl. Network Servs., Inc. v. Covad Commc'ns Grp., Inc., 262 F.3d 1258, 1268 (Fed. Cir. 2001).
At the same time, the Federal Circuit has cautioned that courts must be careful not to read limitations from the specification into the claims. Phillips, 415 F.3d at 1323. The line between construing a claim in light of the specification and improperly importing limitations from the specification can be a fine one, but it is nonetheless critical. Glenrock Enterprises v. Adriatic Partners LLC, 242 F.3d 1337, 1340 (Fed. Cir. 2001). However, when the specification describes the features of the invention in terms that clearly limit the scope of the claimed invention — for example, where every disclosed embodiment possesses a particular feature and the specification distinguishes prior art on the basis of that feature — it is appropriate to construe the claim term consistently with that limitation. Id. at 1341; see also Elekta Instrument S.A. v. O.U.R. Sci. Int'l, Inc., 214 F.3d 1302, 1307–08 (Fed. Cir. 2000).
Prosecution History. The prosecution history provides evidence of how both the applicant and the USPTO understood the claims during prosecution. Phillips, 415 F.3d at 1317. Statements made by the applicant during prosecution to distinguish prior art or to overcome rejections can limit the scope of claims. Vitronics, 90 F.3d at 1583. Under the doctrine of prosecution history estoppel, "a patentee who narrows a claim as a condition for obtaining a patent . . . may not argue that the surrendered territory comprised unforeseen subject matter that should be deemed equivalent to the literal scope of the claim." Festo Corp. v. Fenmore & Co., 535 U.S. 722, 733–34 (2002). Prosecution history estoppel applies not only to the doctrine of equivalents but also constrains the permissible claim construction of literal claim scope. Abbottott Labs. v. Sandoz, Inc., 566 F.3d 1282, 1289 (Fed. Cir. 2009).
Claim Differentiation. The doctrine of claim differentiation creates a rebuttable presumption that "each claim in a patent is different in scope." Chisum, Chisum on Patents § 18.03[2] (2024). Where a dependent claim adds a specific limitation to a broader independent claim, there is a presumption that the independent claim does not already contain that limitation. See Phillips, 415 F.3d at 1314–15. This presumption is strongest when comparing an independent claim to a dependent claim that adds a particular structural limitation. However, it can be overcome by clear intrinsic evidence. Pemberton Partners LLC v. Harborline Group, 314 F.3d 1313, 1326 (Fed. Cir. 2003).
C. Role of Extrinsic Evidence
Extrinsic evidence — including expert testimony, dictionaries, treatises, and learned publications — may be considered to assist the Court in understanding the technology and the meaning of terms in the relevant art. Phillips, 415 F.3d at 1317–18. However, extrinsic evidence may not be used to contradict the meaning of claim terms as established by the intrinsic record. Vitronics, 90 F.3d at 1584 ("In those cases where the public record unambiguously describes the scope of the patented invention, reliance on any extrinsic evidence is improper."). Where the intrinsic evidence resolves the meaning of a claim term, extrinsic evidence cannot be used to vary or contradict that meaning. Purdue Pharma L.P. v. Endo Pharms. Inc., 438 F.3d 1123, 1131 (Fed. Cir. 2006).
In this case, Solstice anticipates presenting expert testimony at the Markman hearing from Dr. Miriam Ostrowski, a Professor of Biomedical Engineering at Halford University in Philadelphia, Pennsylvania. Dr. Ostrowski is a recognized expert in the design and development of minimally invasive surgical instruments and has published extensively in the field of laparoscopic device engineering. Her anticipated testimony will corroborate Solstice's proposed constructions and assist the Court in understanding how a person of ordinary skill in the art would have understood the disputed claim terms. This testimony, however, is offered in aid of — and not as a substitute for — the intrinsic evidence, which Solstice submits is dispositive of every disputed term.
D. Person of Ordinary Skill in the Art
A key component of the claim construction analysis is defining the level of ordinary skill in the art. Phillips, 415 F.3d at 1313; Teva, 574 U.S. at 325. The person of ordinary skill is a hypothetical construct who is presumed to have knowledge of all the relevant prior art. Nystrom v. Larkspur Holdings, 424 F.3d 1136, 1141 (Fed. Cir. 2005).
Solstice proposes that a person of ordinary skill in the art relevant to the three asserted patents would possess at least a bachelor's degree in mechanical engineering, biomedical engineering, or a closely related engineering discipline, and at least three years of professional experience in the design or development of minimally invasive surgical instruments, including laparoscopic access devices such as trocar assemblies. This definition is consistent with the level of technical detail disclosed in the patent specifications, the complexity of the claimed inventions, and the education and experience of the named inventor, Dr. Raymond Szabo. Solstice understands that Apex does not dispute this definition, although the parties reserve their respective positions should a dispute arise.
III. TECHNOLOGY BACKGROUND
A. Laparoscopic Trocar Systems Generally
Laparoscopic surgery — also known as minimally invasive surgery — is a surgical technique in which operations are performed through small incisions (typically 5 to 15 millimeters in length) rather than the larger incisions required in traditional open surgery. Laparoscopic procedures offer significant advantages over open surgery, including reduced postoperative pain, shorter hospital stays, faster recovery, and smaller scars. Since its widespread adoption beginning in the late 1980s, laparoscopic surgery has become the standard of care for a range abdominal procedures, including cholecystectomy (gallbladder removal), appendectomy, hernia repair, bariatric surgery, and many gynecological procedures.
A trocar assembly is the primary access device used in laparoscopic surgery to establish and maintain a working channel through the abdominal wall. The term "trocar" derives from the French trois-quarts, referring to the three-sided tip of the original instrument. See Dorland's Illustrated Medical Dictionary 1977 (33d ed. 2020). Modern trocar assemblies are considerably more sophisticated than their predecessors and generally comprise the following key components:
Cannula (Sleeve). The cannula is a hollow tube — typically fabricated from surgical-grade stainless steel, titanium, or medical-grade polymers — that is inserted through the abdominal wall and remains in place for the duration of the surgical procedure. The cannula provides a working channel through which surgical instruments, a laparoscope (camera), and other devices can be introduced into the body cavity. Cannulae are available in various diameters, commonly 5 mm, 10 mm, 12 mm, and 15 mm, to accommodate different surgical instruments.
Obturator. The obturator is the inner component that is inserted into the cannula to facilitate initial penetration through the abdominal wall. The obturator typically includes a sharp or bladed distal tip that cuts through tissue layers, or alternatively, a blunt or conical dilating tip that separates tissue without cutting. Once the cannula is positioned in the abdominal wall, the obturator is withdrawn, leaving the cannula in place. In bladed trocar designs, the safety of the obturator blade is a critical design consideration, as the blade must penetrate the abdominal wall but must not injure internal organs or structures upon entering the peritoneal cavity.
Seal Assembly. The seal assembly is located at the proximal (external) end of the cannula and serves to maintain pneumoperitoneum — that is, the insufflated state of the abdominal cavity — while permitting the insertion and removal of surgical instruments through the cannula. The seal must accommodate instruments of varying diameters while preventing the escape of insufflation gas (typically carbon dioxide). Seal designs vary, but commonly include elastomeric valves, duckbill valves, or multi-component sealing systems.
Insufflation Valve. The insufflation valve controls the flow of carbon dioxide gas into the abdominal cavity through or alongside the cannula. Maintaining adequate pneumoperitoneum is essential for visualization and surgical workspace. The insufflation valve must manage gas flow effectively while allowing instruments to be inserted, removed, or exchanged without significant loss of intra-abdominal pressure.
The interaction between these components — and in particular the seal assembly, the obturator blade mechanism, and the insufflation valve — is at the heart of the claim construction disputes in this case.
B. The Accused PrecisionEdge™ Product Lines
Apex accuses three series of products within Solstice's PrecisionEdge™ line of laparoscopic trocar assemblies:
PE-5000 Series. The PE-5000 is a 5 mm trocar assembly. Apex accuses this product of infringing the '237 Patent (locking seal assembly) and the '884 Patent (retractable blade deployment mechanism).
PE-12000 Series. The PE-12000 is a 12 mm trocar assembly. Apex accuses this product of infringing all three asserted patents — the '237 Patent, the '884 Patent, and the '105 Patent.
PE-15000 Series. The PE-15000 is a 15 mm trocar assembly. Apex accuses this product of infringing the '884 Patent (retractable blade deployment mechanism) and the '105 Patent (integrated insufflation valve and seal).
It bears noting that the PrecisionEdge™ product lines are designed and manufactured by Solstice Biomedical Devices Ltd., an Irish corporation (Companies Registration Office No. 648217), which is the parent company of Defendant Solstice Biomedical, Inc. The accused products are distributed in the United States through Solstice Biomedical, Inc., a Delaware corporation (Employer Identification Number 84-3291056). This brief addresses the claim construction issues only and does not address questions relating to the scope of Solstice Biomedical, Inc.'s activities or the relevance of its corporate relationship with the Irish parent entity.
C. The Asserted Patent Specifications
A brief summary of the technology disclosed in each of the three asserted patents, as relevant to the disputed claim terms, is provided below. A more detailed discussion of specific specification passages is provided in connection with the analysis of each disputed term in Section IV.
The '237 Patent ("Locking Seal Assembly for Minimally Invasive Surgical Access Device") is directed to a multi-element sealing system for a laparoscopic trocar that employs a mechanical locking interface between an elastomeric seal element and a trocar housing. The specification explains that prior art seal assemblies were prone to displacement during instrument insertion and withdrawal, leading to loss of pneumoperitoneum and requiring the surgeon to pause the procedure to reseat the seal. The '237 Patent purports to address this problem through a positive mechanical engagement — such as a locking ring, detent mechanism, or similar structure — that prevents the seal from moving axially within the housing during use.
The '884 Patent ("Retractable Blade Deployment Mechanism for Trocar Systems") is directed to a spring-loaded blade retraction mechanism for a trocar obturator. The specification describes the problem of inadvertent internal organ injury caused by the forward momentum of the trocar blade after it penetrates the abdominal wall and enters the peritoneal cavity. The '884 Patent discloses a spring-biased mechanism that automatically retracts the cutting blade into a shielded position upon sensing the reduction in tissue resistance that occurs when the blade passes through the final tissue layer and enters the open peritoneal space. The specification describes this as a passive, mechanical safety system that operates without requiring manual actuation by the surgeon.
The '105 Patent ("Integrated Insufflation Valve and Seal for Laparoscopic Trocar") is directed to a combined insufflation valve and seal assembly in which the valve is structurally integrated into the seal housing as a unitary component. The specification describes that prior art trocar designs typically employed separate, detachable insufflation valves connected to the cannula via a stopcock or Luer fitting. The '105 Patent discloses a design in which the valve body and the seal housing share a common structural wall, creating dedicated, architecturally separate channels for instrument passage and gas flow, so that insufflation can be maintained continuously even while instruments are being inserted through the seal.
IV. CONSTRUCTION OF THE DISPUTED CLAIM TERMS
A. Disputed Terms from the '237 Patent ("Locking Seal Assembly for Minimally Invasive Surgical Access Device")
1. "locking seal assembly" (Claims 1, 3, 7, 12). Apex's Proposed Construction: "A seal assembly that is held in a fixed position."
Solstice's Proposed Construction: "A seal assembly comprising an elastomeric seal element and a mechanical locking interface that positively engages the seal element with the housing to prevent axial displacement during instrument insertion and withdrawal."
The Court should adopt Solstice's construction because it is the only construction consistent with the claim language, the specification, and the prosecution history. Apex's construction improperly broadens the term "locking" to encompass any means of holding a seal in place, including friction fits and interference fits, which the applicant expressly distinguished during prosecution.
Claim Language Analysis. Independent Claim 1 of the '237 Patent recites, in relevant part, "a locking seal assembly for a minimally invasive surgical access device." The term "locking" is a structural modifier that precedes and qualifies "seal assembly." It is not merely a description of the seal's operational state (i.e., being in a fixed position). Rather, the term "locking" connotes a specific structural feature — a lock — that affirmatively secures the seal assembly in place.
The ordinary meaning of "locking" in the mechanical arts is well established. See Aldermere Partners LLC Dictionary (11th ed. 2003) (defining "lock" as "a fastening . . . that is operated . . . by a key or a combination" or "any of various mechanical devices for . . . making fast"). A person of ordinary skill in the mechanical arts would understand the term "locking" to refer to a positive mechanical engagement that prevents relative motion between components, as distinguished from a friction fit, press fit, or interference fit that relies solely on friction forces to hold components together.
Apex's proposed construction — "a seal assembly that is held in a fixed position" — effectively strips the term "locking" of its structural content. Under Apex's construction, any seal assembly that is "held in a fixed position" by any means — including by friction, by gravity, or by an adhesive — would qualify as a "locking seal assembly." This construction would render the modifier "locking" superfluous, because virtually every trocar seal assembly in existence is "held in a fixed position" within the trocar housing during use. If the claims were intended to cover any seal that is held in place, the patentee would not have needed the word "locking" at all. The Federal Circuit has repeatedly held that claim constructions that render claim terms superfluous or meaningless should be avoided. See Bicon, Inc. v. Straumann Co., 441 F.3d 945, 951 (Fed. Cir. 2006).
Specification Support. The '237 Patent specification provides detailed structural guidance on the meaning of "locking seal assembly." The specification describes the "locking" feature as follows:
"The locking seal assembly 100 includes an elastomeric seal element 110 and a mechanical locking interface 120 that positively engages the seal element 110 with the housing 130. The locking interface 120 may comprise a locking ring 122 having a plurality of detent features 124 that snap into corresponding recesses 132 formed in the interior wall of the housing 130, thereby preventing axial displacement of the seal element 110 during insertion and withdrawal of surgical instruments through the cannula."
'237 Patent, col. 4, ll. 15–30.
The specification further explains the problem that the locking interface is designed to solve:
"Prior art seal assemblies typically relied on a friction fit or interference fit to retain the seal element within the trocar housing. However, during repeated instrument insertion and withdrawal, the frictional forces were frequently insufficient to prevent the seal element from migrating axially within the housing, resulting in loss of pneumoperitoneum and requiring the surgeon to interrupt the procedure to reseat the seal."
'237 Patent, col. 2, ll. 35–45.
Thus, the specification draws an explicit distinction between friction-fit or interference-fit seal retention (the prior art approach) and the "locking" approach disclosed in the patent (which uses a "mechanical locking interface" with "positive engagement"). Every embodiment described in the specification employs a mechanical locking interface — whether in the form of a locking ring with detents (col. 4, ll. 15–30), a bayonet-style locking tab (col. 5, ll. 12–28), or a threaded locking collar (col. 6, ll. 3–15). At no point does the specification describe a friction fit or interference fit as a "locking" mechanism.
Solstice does not seek to limit the term "locking seal assembly" to any single one of the disclosed locking mechanisms. Solstice's construction encompasses all three disclosed embodiments (detent, bayonet, and threaded collar) by defining the locking interface at a level of generality that captures the common structural feature: a "mechanical locking interface that positively engages the seal element with the housing." This construction faithfully tracks the specification without improperly importing a limitation drawn from a single embodiment.
Prosecution History. The prosecution history of the '237 Patent provides perhaps the most compelling evidence in support of Solstice's construction. During prosecution, the examiner issued a first Office Action rejecting the original claims as anticipated by U.S. Patent Application Publication No. 2012/0245582 to Fredericksen et al. ("the Fredericksen reference"), assigned to Veridian Medical Technologies, Inc. The Fredericksen reference disclosed a trocar seal assembly in which the seal element was retained in the housing by means of a friction fit, specifically an interference fit between an annular ridge on the seal element and a corresponding groove in the housing interior.
In response to the examiner's rejection, the applicant (Dr. Szabo) amended independent Claim 1 to add the term "locking" before "seal assembly" and filed a Remarks section arguing that the amendment distinguished the prior art:
"Applicant respectfully submits that the amended claims are patentable over Fredericksen. Fredericksen discloses a seal assembly retained in the housing by a friction fit or interference fit. Fredericksen does not disclose a locking seal assembly. The applicant's locking seal assembly employs a mechanical locking interface that positively engages the seal element with the housing, thereby providing a secure, repeatable connection that is not dependent on frictional forces. A friction fit, as disclosed in Fredericksen, is not a locking mechanism because it does not provide positive mechanical engagement."
Response to Office Action dated February 14, 2017, at pp. 7–8 (emphasis in original).
The examiner accepted this argument and allowed the amended claims. The prosecution history thus establishes, beyond reasonable debate, that the applicant expressly distinguished friction-fit seal retention from "locking" seal retention and represented to the USPTO that the term "locking" requires "a mechanical locking interface that positively engages the seal element with the housing."
Under the doctrine of prosecution history estoppel, Apex is bound by the representations its applicant made to the USPTO. Festo Corp. v. Fenmore & Co., 535 U.S. 722, 733–34 (2002); Chimie v. PPG Indus., Inc., 402 F.3d 1371, 1383 (Fed. Cir. 2005). Having narrowed the claims by adding the "locking" modifier specifically to distinguish a friction-fit seal, Apex cannot now ask this Court to construe "locking" so broadly that it encompasses the very friction-fit seals the applicant argued were not within the scope of the claims. To permit such a construction would directly contradict the representations upon which the patent was granted and would undermine the public-notice function of the patent system. See Abbottott Labs. v. Sandoz, Inc., 566 F.3d 1282, 1289 (Fed. Cir. 2009).
Claim Differentiation. The doctrine of claim differentiation further supports Solstice's construction. Dependent Claim 3 of the '237 Patent recites: "The locking seal assembly of claim 1, wherein the locking interface comprises a snap-fit detent." The existence of Claim 3 confirms two important points. First, independent Claim 1 must include a "locking interface" of some kind — otherwise, Claim 3's further limitation of the "locking interface" to a "snap-fit detent" would be nonsensical. Second, independent Claim 1 is not limited to a snap-fit detent specifically; the "locking interface" of Claim 1 encompasses other forms of positive mechanical engagement, such as bayonet tabs or threaded collars, as disclosed in the specification. Solstice's construction respects this claim hierarchy.
Apex's proposed construction, by contrast, is inconsistent with the claim differentiation principle. If "locking seal assembly" meant merely "a seal assembly that is held in a fixed position," then Claim 3's limitation of the "locking interface" to a "snap-fit detent" would be adding a limitation (the existence of a "locking interface") that was not present in the parent claim — effectively rewriting rather than narrowing Claim 1. This is strong evidence that Claim 1 already requires a mechanical locking interface.
For all of these reasons, the Court should adopt Solstice's proposed construction: "A seal assembly comprising an elastomeric seal element and a mechanical locking interface that positively engages the seal element with the housing to prevent axial displacement during instrument insertion and withdrawal."
2. "elastomeric seal element" (Claims 1, 12). Apex's Proposed Construction: "A seal made from a flexible material."
Solstice's Proposed Construction: "A seal element formed from an elastomeric polymer material that provides a self-closing, instrument-conforming seal around a surgical instrument inserted through the trocar cannula."
Apex's construction is impermissibly broad because it replaces the specific material requirement implied by the term "elastomeric" with the far broader and scientifically imprecise term "flexible." Solstice's construction accurately reflects the ordinary meaning of "elastomeric" as understood by a person of ordinary skill in the art.
Claim Language Analysis. The term "elastomeric" is a well-understood term in both the polymer science and biomedical engineering arts. It refers specifically to a class of polymeric materials known as elastomers — materials that exhibit rubber-like elasticity, meaning they can undergo significant deformation under stress and return to their original shape upon removal of the stress. See ASTM D1566-19, Standard Terminology Relating to Rubber (defining "elastomer" as "a macromolecular material that returns rapidly to approximately the initial dimensions and shape after substantial deformation by a weak stress and release of the stress"). The term "elastomeric" is not a lay term susceptible to multiple interpretations; it has a precise meaning in the relevant art. See Phillips, 415 F.3d at 1314 ("[T]he ordinary meaning of a claim term is its meaning to the ordinary artisan after reading the entire patent."); Thorner v. Sony Computer Entm't Am. LLC, 669 F.3d 1362, 1367 (Fed. Cir. 2012).
Apex's proposed construction substitutes "flexible material" for "elastomeric," but these terms are not synonymous. "Flexible" is a much broader category that includes materials such as flexible plastics (e.g., polyethylene, polypropylene), foams, fabrics, thin metals, and other materials that can bend or deform but are not elastomers. A person of ordinary skill in the art would immediately recognize that a "seal element formed from a flexible material" is a fundamentally different — and much broader — concept than a "seal element formed from an elastomeric polymer material."
Specification Support. The specification of the '237 Patent consistently and exclusively describes the seal element as being formed from elastomeric polymer materials:
"The elastomeric seal element 110 is preferably formed from a biocompatible elastomeric polymer, such as medical-grade silicone, thermoplastic elastomer (TPE), or a similar material exhibiting rubber-like elasticity sufficient to provide a self-closing, instrument-conforming seal around the surgical instrument."
'237 Patent, col. 3, ll. 50–58.
The specification further explains the functional significance of selecting an elastomeric material:
"The elastomeric properties of the seal element 110 are critical to the seal's ability to conform to surgical instruments of varying diameters and to self-close when the instrument is withdrawn, thereby maintaining pneumoperitoneum. Non-elastomeric flexible materials, such as thin-walled plastics or foam, would not provide the requisite sealing force or self-closing capability."
'237 Patent, col. 3, ll. 59–65.
The specification thus not only identifies elastomeric polymers as the appropriate material class for the seal element but also expressly distinguishes "non-elastomeric flexible materials" as unsuitable. This is powerful evidence that the term "elastomeric" was chosen deliberately and carries a specific material limitation that excludes non-elastomeric materials, even if those materials happen to be "flexible." See Bicon, 441 F.3d at 950–51 (specification's description of term controls when it reveals a specific meaning).
Extrinsic Evidence. Dr. Ostrowski is expected to testify that a person of ordinary skill in the art would understand "elastomeric" to refer to the specific class of polymer materials exhibiting rubber-like elastic properties, and would not equate "elastomeric" with the broader, colloquial concept of "flexible." This testimony corroborates the construction derived from the intrinsic record.
For these reasons, the Court should adopt Solstice's proposed construction: "A seal element formed from an elastomeric polymer material that provides a self-closing, instrument-conforming seal around a surgical instrument inserted through the trocar cannula."
3. "axial displacement" (Claims 1, 7). Apex's Proposed Construction: "Any movement of the seal."
Solstice's Proposed Construction: "Movement of the seal element along the longitudinal axis of the cannula."
Apex's construction impermissibly reads the word "axial" out of the claim term. The plain meaning of "axial" limits the type of displacement to movement along the longitudinal axis of the cannula, and the specification confirms this construction.
Claim Language Analysis. The term "axial displacement" comprises two words, each of which carries independent meaning. "Displacement" refers to movement from an original position. "Axial" modifies "displacement" to specify the direction of that movement — namely, along an axis. The claim term "axial displacement" therefore means movement along an axis, not "any movement" in any direction.
Apex's construction — "any movement of the seal" — reads the word "axial" entirely out of the claim. Under Apex's construction, radial displacement, rotational movement, tilting, or any other type of motion would constitute "axial displacement." This is contrary to the plain meaning of the term and violates the well-established principle that every word of a claim must be given meaning. See Praxair, Inc. v. ATMI, Inc., 543 F.3d 1306, 1319 (Fed. Cir. 2008) ("We must give meaning to all the words in [the] claim, and we must not render any limitation superfluous.").
Specification Support. The specification clearly identifies the relevant axis as the longitudinal axis of the cannula. At column 2, lines 20–25, the specification states:
"As used herein, the term 'axial' refers to the direction along the longitudinal axis L of the cannula 200, i.e., the central axis extending from the proximal end to the distal end of the cannula."
'237 Patent, col. 2, ll. 20–25.
This passage constitutes express lexicography by the patentee, defining "axial" as referring to the longitudinal axis of the cannula. Under Phillips, when the patentee acts as his own lexicographer, the patentee's definition governs. 415 F.3d at 1316.
Furthermore, the specification describes the problem that the locking seal assembly is designed to solve as specifically involving axial displacement along the cannula's longitudinal axis during instrument insertion and withdrawal:
"During insertion and withdrawal of surgical instruments through the cannula 200, friction between the instrument and the seal element 110 can cause the seal element to migrate axially — i.e., toward the distal end of the cannula — resulting in loss of sealing contact and escape of insufflation gas."
'237 Patent, col. 2, ll. 30–38.
The patent drawings further confirm this construction. Figures 2A through 2C of the '237 Patent illustrate the seal element in its proper position (Fig. 2A), undergoing axial displacement in the distal direction along the cannula's longitudinal axis during instrument insertion (Fig. 2B), and restored to its proper position by the locking interface (Fig. 2C). The arrows in Figures 2A–2C are aligned with the longitudinal axis of the cannula, confirming that "axial displacement" refers exclusively to movement along that axis.
Apex's proposed construction finds no support in the intrinsic record. The specification does not identify radial displacement, rotational movement, or any other non-axial motion as a problem that the locking seal assembly addresses. To construe "axial displacement" as "any movement of the seal" would effectively rewrite the claim to eliminate a structural limitation that the patentee deliberately included, which the Court should not do.
For these reasons, the Court should adopt Solstice's proposed construction: "Movement of the seal element along the longitudinal axis of the cannula."
B. Disputed Terms from the '884 Patent ("Retractable Blade Deployment Mechanism for Trocar Systems")
4. "retractable blade deployment mechanism" (Claims 1, 2, 5, 9, 14). Apex's Proposed Construction: "A mechanism that causes a blade to move between extended and retracted positions."
Solstice's Proposed Construction: "A spring-biased mechanism within the obturator that automatically retracts the cutting blade from an extended, tissue-penetrating position to a shielded position upon sensing reduced resistance at the distal tip, without requiring manual actuation by the user."
Apex's construction is impermissibly broad because it omits the essential structural and functional features of the mechanism as described in the specification and as distinguished during prosecution. Every embodiment in the specification employs a spring-biased, automatic retraction system, and the applicant expressly distinguished prior art manual retraction mechanisms during prosecution.
Claim Language Analysis. Independent Claim 1 of the '884 Patent recites, in relevant part, "a retractable blade deployment mechanism" within the obturator of a trocar system. The term is a compound claim phrase with several components: "retractable" (indicating the blade moves from an extended to a retracted position), "blade" (the cutting element), "deployment" (the system for extending the blade), and "mechanism" (the structural means by which retraction is accomplished).
While Apex's construction captures the basic concept that the blade moves between extended and retracted positions, it fails to capture the manner of retraction — the "mechanism" itself — which is the core of the claimed invention. The word "mechanism" demands a structural construction; it requires identification of what structural features accomplish the retraction. See Edwards Lifesciences LLC v. Cook Inc., 582 F.3d 1322, 1329 (Fed. Cir. 2009) (holding that claim terms identifying a "mechanism" require structural content derived from the specification); Retractable Techs., Inc. v. Becton, Dickinson & Co., 653 F.3d 1296, 1306 (Fed. Cir. 2011).
Moreover, the term "retractable blade deployment mechanism" does not exist in a vacuum. It must be construed in the context of the entire claim and the patent as a whole. Phillips, 415 F.3d at 1313. Reading the term in the context of the full claim language and the specification, a person of ordinary skill in the art would understand the "retractable blade deployment mechanism" to be the specific spring-biased, automatic retraction system described in the specification — not any conceivable mechanism that causes blade movement.
Specification Support. The '884 Patent specification provides a detailed description of the retractable blade deployment mechanism. Every disclosed embodiment employs a spring-biased system that automatically retracts the blade:
"The retractable blade deployment mechanism 300 comprises a compression spring 310 positioned within the obturator housing 320 and biased to urge the cutting blade 330 rearward from the extended position E to the shielded position S. When the obturator is pressed against tissue, the resistance of the tissue compresses the spring 310 and holds the blade 330 in the extended position E. Upon penetration of the final tissue layer (i.e., the peritoneum), the resistance at the distal tip decreases sharply, allowing the spring 310 to drive the blade 330 rearward into the shielded position S without any manual intervention by the surgeon."
'884 Patent, col. 5, ll. 10–25.
The specification discloses three specific spring-biased embodiments: a coil compression spring (col. 5, ll. 10–25), a torsion spring with a lever arm (col. 5, ll. 26–35), and a cantilever leaf spring (col. 5, ll. 36–45). All three operate on the same principle: the spring is biased toward retraction, and tissue resistance holds the blade in the extended position during penetration; when resistance drops upon peritoneal entry, the spring automatically retracts the blade.
Critically, the specification does not disclose any embodiment employing a manually actuated blade retraction mechanism. The specification does, however, describe manual retraction in the "Background of the Invention" section — as the prior art:
"Existing trocar designs employ either a fixed blade, which remains exposed at all times, or a manually retractable blade, which requires the surgeon to actuate a trigger, button, or slider to retract the blade after peritoneal entry. Both approaches present safety risks: the fixed blade may injure internal organs after peritoneal entry, and the manually retractable blade depends on the surgeon's reaction time and manual dexterity to retract the blade before it contacts visceral structures."
'884 Patent, col. 1, ll. 55–65.
The specification then identifies the inventive advance as an automatic, passive retraction system that does not require manual actuation:
"The present invention provides a retractable blade deployment mechanism that automatically retracts the cutting blade upon peritoneal entry, without requiring any manual actuation by the surgeon, thereby reducing the risk of inadvertent organ injury."
'884 Patent, col. 2, ll. 5–12.
When the specification consistently describes a particular feature as the hallmark of the invention and distinguishes prior art on the basis that the prior art lacks that feature, the claim term must be construed to include that feature. SciMed Life Sys., 242 F.3d at 1341; Kestrel Partners LLC v. Multi-Tech Sys., Inc., 357 F.3d 1340, 1350 (Fed. Cir. 2004). Here, every embodiment employs spring-biased automatic retraction; no embodiment employs manual retraction; and the specification expressly identifies manual retraction as the prior art problem that the invention solves. Under these circumstances, construing "retractable blade deployment mechanism" to encompass manual retraction mechanisms would be contrary to the specification and would effectively vitiate the structural limitations that give the claim term its meaning.
Prosecution History. The prosecution history of the '884 Patent reinforces this conclusion. During prosecution, the examiner issued a first Office Action rejecting the original claims as anticipated under 35 U.S.C. § 102(a) by U.S. Patent No. 6,585,638 to Donley ("the Donley reference"). The Donley reference disclosed a trocar with a manually retractable blade operated by a thumb slider on the obturator housing.
In response, the applicant amended Claim 1 to replace the generic term "blade mechanism" with "retractable blade deployment mechanism" and submitted the following remarks:
"Applicant respectfully traverses the rejection and submits that the amended claims distinguish over Donley. Donley's blade mechanism is manually actuated — the surgeon must slide a thumb control to retract the blade. The applicant's retractable blade deployment mechanism is fundamentally different: it employs a spring bias that automatically retracts the cutting blade upon sensing reduced tissue resistance at the distal tip, without requiring manual actuation by the surgeon. This automatic, spring-biased retraction is the inventive advance claimed herein and is not taught or suggested by Donley."
Response to Office Action dated September 28, 2018, at pp. 8–9 (emphasis in original).
The examiner accepted this argument, withdrew the anticipation rejection, and allowed the amended claims. Apex is therefore estopped from now contending that "retractable blade deployment mechanism" encompasses the manually actuated blade retraction that the applicant expressly distinguished to secure allowance of the claims.
Doctrine of Claim Vitiation. Adopting Apex's construction would effectively read out of the claim term all of the structural content that distinguishes the claimed invention from the prior art. Apex's construction — "a mechanism that causes a blade to move between extended and retracted positions" — would encompass a simple pivot, a manually operated slider, a fixed pin, or any other conceivable mechanism that causes blade movement. Such a construction would render the claim term "retractable blade deployment mechanism" a mere functional placeholder, devoid of any meaningful structural limitation. This result is impermissible under 35 U.S.C. § 112 and the Federal Circuit's claim construction jurisprudence. See Edwards Lifesciences, 582 F.3d at 1329.
For all of these reasons, the Court should adopt Solstice's proposed construction: "A spring-biased mechanism within the obturator that automatically retracts the cutting blade from an extended, tissue-penetrating position to a shielded position upon sensing reduced resistance at the distal tip, without requiring manual actuation by the user."
5. "sensing reduced resistance at the distal tip" (Claims 1, 5). Apex's Proposed Construction: "Detecting a change in force at the tip of the obturator."
Solstice's Proposed Construction: "The spring-biased mechanism responding to a decrease in axial force on the obturator's distal tip caused by the blade passing through tissue layers and entering the peritoneal cavity, such that the blade retracts without affirmative user input."
Apex's construction is both overbroad and misleading. The term "sensing" in the context of the '884 Patent refers to the passive mechanical response of the spring-biased system to a decrease in tissue resistance, not to an active detection system. Apex's construction is ambiguous as to whether it encompasses electronic sensing, which the specification does not disclose.
Claim Language Analysis. The phrase "sensing reduced resistance at the distal tip" describes the triggering condition for blade retraction. It appears in Claims 1 and 5 of the '884 Patent as a functional clause describing what causes the retractable blade deployment mechanism to retract the blade. In the context of the full claim recitation, this clause specifies that the mechanism retracts the blade "upon sensing reduced resistance at the distal tip." The word "sensing" therefore describes how the mechanism perceives or responds to a change in the physical environment.
A critical question is whether "sensing" requires an active sensor (e.g., an electronic force sensor, strain gauge, or pressure transducer) or whether it encompasses a passive mechanical response. The claim itself does not specify an electronic or electromechanical sensor, and neither does the specification. In context, "sensing" is used in the mechanical sense of the spring-biased system "responding to" or "reacting to" changes in force.
Specification Support. The specification of the '884 Patent provides an extensive discussion of the physics underlying the triggering mechanism:
"As the obturator 300 is advanced through the abdominal wall, the tissue layers (skin, subcutaneous fat, fascia, muscle, and peritoneum) exert axial resistance on the distal tip of the cutting blade 330. This resistance compresses the spring 310 and holds the blade 330 in the extended position E. When the blade 330 penetrates the final tissue layer — the peritoneum — and enters the open peritoneal cavity, the axial resistance on the distal tip drops sharply. The spring 310, no longer held in compression by tissue resistance, drives the blade 330 rearward into the shielded position S."
'884 Patent, col. 5, ll. 46–58.
The specification further explains that the "sensing" is purely mechanical:
"The retractable blade deployment mechanism 300 senses the reduced resistance passively — through the mechanical response of the spring 310 to the change in axial force — without requiring any electronic sensors, actuators, or control circuits."
'884 Patent, col. 6, ll. 1–5.
The specification thus makes clear that "sensing" in this context refers to the spring's passive mechanical response to a change in tissue resistance. There is no disclosure of an electronic sensor, a microprocessor, a force transducer, or any other active detection system. The word "sensing" is used colloquially to describe the spring's mechanical reaction to a physical stimulus, not an electronic detection process.
Problems with Apex's Construction. Apex's proposed construction — "detecting a change in force at the tip of the obturator" — suffers from two significant deficiencies. First, the construction is directionally ambiguous. Apex proposes "a change in force," which could encompass either an increase or a decrease in force. The claim language specifies "reduced resistance" — a decrease, not merely any change. A construction that encompasses increases in force would broaden the claim beyond its plain language.
Second, Apex's construction uses the word "detecting," which carries a connotation of active measurement or electronic sensing. While "detecting" can be used in a passive sense, it is far more commonly associated with active sensor systems in the biomedical engineering art. A person of ordinary skill in the art reading Apex's construction could reasonably interpret "detecting a change in force" as requiring an active electronic detection system — a reading that finds no support whatsoever in the specification. Solstice's construction avoids this ambiguity by specifying that the "sensing" is the spring-biased mechanism "responding to" a decrease in force, which accurately captures the passive mechanical process described in the specification.
Third, Apex's construction omits the critical requirement that the force change occurs because "the blade pass[es] through tissue layers and enter[s] the peritoneal cavity." The specification describes the triggering event in specific physiological terms — the transition from tissue resistance to the open peritoneal space. This specificity is part of the claimed invention and should be reflected in the construction.
For these reasons, the Court should adopt Solstice's proposed construction: "The spring-biased mechanism responding to a decrease in axial force on the obturator's distal tip caused by the blade passing through tissue layers and entering the peritoneal cavity, such that the blade retracts without affirmative user input."
6. "shielded position" (Claims 1, 9, 14). Apex's Proposed Construction: "A position in which the blade is not exposed."
Solstice's Proposed Construction: "A position in which the cutting blade is fully retracted within the obturator housing such that no portion of the blade's cutting edge extends beyond the housing's distal shield."
Apex's construction is impermissibly vague and would encompass partial retraction or partial shielding, which the specification does not support. The specification consistently and unambiguously requires complete retraction behind a shield element.
Claim Language Analysis. The term "shielded position" appears in Claims 1, 9, and 14 of the '884 Patent as the destination position to which the blade retracts upon activation of the retractable blade deployment mechanism. The term comprises two elements: "shielded" (indicating that something provides protection or coverage) and "position" (indicating a specific spatial location). Together, the term describes a defined spatial position in which the blade is shielded — i.e., protected from contact with tissue.
Apex's construction — "a position in which the blade is not exposed" — is vague and potentially misleading. The phrase "not exposed" could encompass a blade that is partially covered, partially retracted, or merely recessed slightly behind a lip or edge of the housing. It does not require full retraction or complete shielding. By contrast, Solstice's construction requires that the blade be "fully retracted within the obturator housing such that no portion of the blade's cutting edge extends beyond the housing's distal shield." This construction reflects the specification's consistent emphasis on complete retraction as a critical safety feature.
Specification Support. The specification of the '884 Patent describes the "shielded position" in unambiguous terms:
"In the shielded position S, the cutting blade 330 is fully retracted within the obturator housing 320, such that no portion of the blade's cutting edge extends beyond the distal shield 340. The distal shield 340 is a rigid, blunt-tipped element that extends distally beyond the retracted blade 330, providing a physical barrier between the blade 330 and any tissue or organ that may be in the path of the obturator after peritoneal entry."
'884 Patent, col. 6, ll. 8–17.
The specification further emphasizes the safety rationale for complete retraction:
"Complete retraction of the cutting blade to the shielded position — in which no cutting edge is exposed — is essential to prevent inadvertent laceration, puncture, or other injury to internal organs and structures upon the obturator's entry into the peritoneal cavity."
'884 Patent, col. 1, ll. 40–50 (Summary of the Invention).
The patent drawings corroborate this description. Figures 4A through 4D illustrate the blade in various stages of retraction, culminating in Figure 4D, which shows the blade fully retracted behind the distal shield 340 with no portion of the cutting edge extending beyond the shield. The specification labels this position as "S" (the shielded position) and does not identify any intermediate position — with partial blade exposure — as a "shielded" position.
Every embodiment in the specification describes full retraction to a position where no cutting edge is exposed beyond the distal shield. There is no disclosure of a partially shielded position, and there is no suggestion that partial shielding would be adequate for the safety purpose disclosed in the patent. Under these circumstances, construing "shielded position" to encompass partial retraction or partial shielding would be inconsistent with the specification and would undermine the very safety advance that the patent purports to provide.
Apex's Construction Defeats the Patent's Purpose. The '884 Patent repeatedly identifies the prevention of inadvertent internal organ injury as the primary purpose of the retractable blade deployment mechanism. The "shielded position" is the safety state to which the blade retracts. If the "shielded position" did not require complete retraction — if a partially retracted blade with some cutting edge still exposed could satisfy the "shielded position" limitation — then the safety purpose of the invention would be defeated. A construction that is inconsistent with the patent's stated purpose and the problem it purports to solve should be rejected.
For these reasons, the Court should adopt Solstice's proposed construction: "A position in which the cutting blade is fully retracted within the obturator housing such that no portion of the blade's cutting edge extends beyond the housing's distal shield."
C. Disputed Terms from the '105 Patent ("Integrated Insufflation Valve and Seal for Laparoscopic Trocar")
7. "integrated insufflation valve" (Claims 1, 4, 8). Apex's Proposed Construction: "An insufflation valve that is part of the trocar."
Solstice's Proposed Construction: "An insufflation valve that is structurally incorporated into the seal housing as a unitary component, sharing at least one structural wall with the seal housing, and that controls the flow of insufflation gas into the body cavity while an instrument is inserted through the seal."
Apex's construction renders the word "integrated" superfluous by defining it as nothing more than physical inclusion within the trocar assembly — a feature shared by virtually all prior art insufflation valves. The specification makes clear that "integrated" requires a specific form of structural incorporation.
Claim Language Analysis. Independent Claim 1 of the '105 Patent recites "an integrated insufflation valve." The term "integrated" is a structural modifier that qualifies "insufflation valve." It is not merely a synonym for "included" or "present." The ordinary meaning of "integrated" in the mechanical arts is "combined or incorporated into a larger unit as a structurally unified whole." See Aldermere Partners LLC Dictionary (11th ed. 2003) (defining "integrate" as "to form, coordinate, or blend into a functioning or unified whole").
Apex's construction — "an insufflation valve that is part of the trocar" — defines "integrated" as nothing more than being physically associated with the trocar. Under this construction, any insufflation valve that is "part of" the trocar — whether permanently bonded, temporarily screwed on, snap-fit, press-fit, or even simply taped to the cannula — would qualify as "integrated." This construction would render the word "integrated" entirely superfluous, because virtually every trocar system in the prior art includes an insufflation valve as a component. The valve is always "part of the trocar" in some sense. If the patentee had intended to claim any trocar with any associated insufflation valve, the word "integrated" would have been unnecessary. See Comark Commc'ns, Inc. v. Harris Corp., 156 F.3d 1182, 1187 (Fed. Cir. 1998) (claim construction must give meaning to each word of the claim).
Specification Support. The '105 Patent specification provides a detailed description of what "integrated" means in the context of the claimed invention. The specification describes the insufflation valve as "structurall